Smith & Nephew plc (LON:SN) Given Average Recommendation of “Hold” by Brokerages

Smith & Nephew plc (LON:SN) has been assigned a consensus recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 1,381.33.

Several analysts recently weighed in on the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,350 target price on shares of Smith & Nephew in a report on Tuesday, March 17th. Panmure Gordon reiterated a “hold” rating and set a GBX 1,200 price target on shares of Smith & Nephew in a report on Tuesday, December 9th. Finally, Berenberg Bank restated a “hold” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a report on Friday, January 23rd.

Smith & Nephew Stock Performance

Shares of SN opened at GBX 1,187.50 on Wednesday. The firm has a 50-day moving average of GBX 1,269.72 and a 200-day moving average of GBX 1,289.82. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90. The stock has a market cap of £13.02 billion, a PE ratio of 42.75, a PEG ratio of 0.46 and a beta of 0.68.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.